This page shows the latest Acorda Therapeutics news and features for those working in and with pharma, biotech and healthcare.
There were two other positive opinions on new medicines at the CHMP meeting last week, with the panel backing Acorda Therapeutics’ inhaled Inbrija (levodopa) for the treatment of symptoms of ‘off’ ... look at two other recent rejections –
Alnylam chief executive John Maraganore, Decibel Therapeutics’ CEO Steve Holtzman, Acorda CEO Ron Cohen and Jeremy Levin of Ovid Therapeutics are the main signatories to the letter published In Nature, but
The biotech company has also been linked to a possible takeover offer for Acorda Therapeutics and its Parkinson’s diseases candidates Inbrija (inhaled levodopa) and SYN-201.
Strikes $363m deal for Finnish firm. Acorda Therapeutics has agreed to buy Finland's Biotie Therapies in a $363m deal that swells its pipeline of Parkinson's disease (PD) drug candidates. ... The deal will also give Acorda four phase III programmes that -
TBR 652 is currently being developed by Tobira Therapeutics. A phase IIa proof-of-concept trial evaluated the antiviral activity, safety and pharmacokinetics of TBR 652 in treatment-experienced, CCR5-naïve ... Philippines. Dalfampridine . Ampyra
The drug will be manufactured by Irish pharmaceutical company, Elan, and will be distributed in the US by Acorda Therapeutics. ... Shane Cooke, executive vice president and head of Elan Drug Technologies said: "We wish to congratulate Acorda Therapeutics
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
Clarus Therapeutics pushed through with the launch of its testosterone replacement tablet, Jatenzo, despite the disruption caused by COVID-19. ... execute a successful virtual launch if it is going to compete with drugs such as Inbrija (Acorda
847. Lineage Therapeutics/Impax Laboratories. Company acquisition. Includes generic and branded products such albendazole and epinephrine. ... 675. Acorda Therapeutics/Civitas Therapeutics. Company acquisition. Includes CVT 301 in P3 for Parkinson's as
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Acorda Therapeutics has expanded its board of directors with the addition of Dr Catherine Strader. ... Dr Ron Cohen, Acorda's president and chief executive officer, said: “Catherine brings decades of experience as both a drug developer and
New York-based biotech Acorda Therapeutics has appointed Dr Burkhard Blank as its chief medical officer. ... Burkhard brings to Acorda an impressive record of successful drug development and approved NDAs.
More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.
Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...